BioRestorative Therapies' combined Management Team, Board of Directors and Scientific Advisory Board members have extensive experience in the healthcare industry. Together we have expert experience in the stem cell science, medical-related services, life science services marketing, public company business management and financing, IP development and licensing, business acquisitions, and strategic partnering.
Chief Medical Advisor for Spine Medicine
Dr. Gregory E. Lutz matriculated to Georgetown University School of Medicine in 1984, having graduated from Drew University magna cum laude and Phi Beta Kappa. He graduated from medical school in 1988 and was awarded the Margaret M. Kenrick Achievement Award in Physical Medicine & Rehabilitation. He pursued his specialty training in Physical Medicine & Rehabilitation at the Mayo Clinic in Rochester, MN. Following his residency he completed an Orthopedic Sports Medicine Fellowship at the Hospital for Special Surgery in New York City. Dr. Lutz has been in practice at the Hospital for Special Surgery since 1993.
In 1997, Dr. Lutz founded the Physiatry Department at the Hospital for Special Surgery and became its first Physiatrist-in-Chief. Dr. Lutz remained Physiatrist-in-Chief for 15 years and with the support of the Surgeon-in-Chiefs, Drs. Russell Warren and Thomas Sculco, and his colleagues, the Physiatry Department has become one of the largest outpatient musculoskeletal practices in the world. The Hospital for Special Surgery’s Physiatry Department now consists of 13 physicians who performed over 50,000 patient visits and over 6000 interventional procedures in 2012.
Dr. Lutz established the Physiatry Spine & Sports Medicine Fellowship in 1997 and has mentored over 50 fellows in practice throughout the USA. In addition, the Physiatry Department has an integral role in teaching residents from the Columbia/Cornell combined residency program. Dr. Lutz has numerous scientific publications, book chapters, and research grants. In 2004, Dr. Lutz received the PASSOR (Physiatric Association for Spine Sports and Occupational Rehabilitation) Research Award, given to one physiatrist nationally who has demonstrated excellence in musculoskeletal research.
Dr. Lutz is currently the Physiatrist-in-Chief Emeritus for the Hospital for Special Surgery and is a member of their board of trustees. He is an Associate Professor of Clinical Rehabilitation Medicine, Weill Medical College of Cornell, and a Consultant Physician to the National Hockey League Players’ Association. Dr Lutz recently founded the Regenerative SportsCare Institute in the Upper East Side of Manhattan - a center dedicated to the regenerative musculoskeletal care of athletes of all ages and levels. In addition, Dr. Lutz is the co-founder of two privately held biotechnology companies. Orthobond Corporation provides proprietary nanocoatings to improve the safety and function of medical devices. Interventional Regenerative Orthotherapeutics provides minimally invasive spinal delivery devices to improve the safety and efficacy of interventional spinal procedures.
Scientific Advisory Board
Wayne A. Marasco, M.D., Ph.D. is Chairman of our Scientific Advisory Board. Dr. Marasco is a principal faculty member of Harvard Stem Cell Institute, a Professor in the Department of Cancer Immunology & AIDS at the Dana-Farber Cancer Institute, and a Professor of Medicine at Harvard Medical School. He is a licensed physician-scientist with training in internal medicine and specialty training in infectious diseases. His clinical practice sub-specialty is in the treatment of immuno-compromised (cancer, bone marrow and solid organ transplant) patients.
Dr. Marasco is the Founding Scientific Director of National Foundation for Cancer Center for Therapeutic Antibody Engineering, Center for Human Antibody Therapies (“CHAT”) and Humanized Neonatal Mouse Center (“HNMC”) (www.humouse.org) at the Dana-Farber Cancer Institute. CHAT and HNMC are affiliated research programs of the Harvard Stem Cell Institute (www.hsci.harvard.edu).
Most recently, Dr. Marasco was co-founder and Chairman of the Scientific Advisory Board and Medical Advisory Board of NeoStem, Inc., a publicly traded adult stem cell company (NYSE MKT:NBS). In 1995, Dr. Marasco founded IntraImmune Therapies, Inc., a gene therapy and antibody engineering company, and served as the Chairman of its Scientific Advisory Board until the company was acquired by Abgenix in 2000. Dr. Marasco has also served as a scientific advisor to several biotechnology companies working in the field of antibody engineering, gene discovery, gene therapy and stem cell therapy.
Dr. Marasco’s research laboratory (www.marascolab.org) is focused on translational medicine in two broad areas. First is in the area of therapeutic human monoclonal antibody development. His laboratory is pioneering the use of antibody immunotherapy to prevent and treat emerging infectious diseases such as influenza, SARS, West Nile Virus, HIV and other human diseases including cancer. The second area is in the development of humanized mice to study adult stem cell development, differentiation and their applications for regenerative medicine.
In 2003, Dr. Marasco founded the National Foundation of Cancer Research Center for Therapeutic Antibody Engineering to expand the use of human monoclonal antibodies in the treatment of cancer. In 2009, he was listed among 13 top scientists in their field as the 21st century medicine "Pioneeers of Medicine Progress" by US News & World Report.
Dr. Marasco received his Ph.D. in 1980 from the University of Connecticut School of Medicine and postdoctoral training at the University of Michigan Medical School, where he also earned an M.D. in 1986 and completed training in internal medicine. He received his subspecialty training in infectious diseases at Harvard Medical School, and joined the Dana-Farber Cancer Institute in 1989. Dr. Marasco has authored over 110 peer-reviewed scientific publications, over 25 reviews, chapters, monographs and editorials and is listed as the inventor on 36 patents. He has been a keynote speaker at many national and international meetings in these research areas.
Dr. Cavagnaro joined BioRestorative Therapies’ Scientific Advisory Board in January 2015. She is currently the President and Founder of Access BIO, L.C., located in Boyce, Virginia, a company providing consultant services specializing in science-based regulatory strategies and development services to facilitate translation of biomedical research, emerging technologies and product development. Her career spans academia, the clinical research organization and biotechnology industries and government. Dr. Cavagnaro is well published, serves on Scientific Advisory Boards and consults and lectures internationally.
From 1989 through 1997, Dr. Cavagnaro held positions with the Food and Drug Administration’s (FDA) Center for Biologics Evaluation and Research (CBER), most recently as a Senior Pharmacologist and Director of Quality Assurance in Bethesda, Maryland. Within the FDA, she was responsible for inter-center and international policy guidance for the preclinical development and safety assessment of biological products. She was the spokesperson for CBER at local, national and international meetings related to pharmacology and toxicology aspects of biologic product review. She served as an FDA safety topic lead for the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) initiative and as rapporteur for the ICH S6 guidance on preclinical safety evaluation of biotechnology-derived pharmaceuticals. Dr. Cavagnaro was also appointed to the prestigious U.S. Health and Human Services (HHS) Senior Biomedical Research Service, used by FDA to recruit and retain the most outstanding research and review scientists.
Immediately prior to founding Access BIO, Dr. Cavagnaro was the Vice President of Regulatory Affairs and Integrated Compliance with Human Genome Sciences, Inc., in Rockville, Maryland where she established the Regulatory Affairs Department, which included regulatory affairs and clinical data management data programming functions, and assisted in identifying and developing new pre-clinical opportunities. Preceding her work with the FDA, Dr. Cavagnaro also held a Senior Staff Scientist position in the Department of Toxicology for Covance (formerly Hazleton Labs) in Vienna, Virginia. Here she was the principal study director for pharmaceutical products derived from biotechnology. She planned and executed the program for safety evaluation of biotechnology-derived products in cooperation with appropriate scientific specialists at the company’s laboratories worldwide.
Dr. Cavagnaro’s academic career included positions at the Boston University School of Medicine in Boston, Massachusetts, the Duke University School of Medicine in Durham, North Carolina, and the University of North Carolina School of Medicine in Chapel Hill, North Carolina.
Dr. Cavagnaro is the Past Chair of the Regulatory Affairs Professional Society and the National Capital Area Chapter of the Society of Toxicology. She is a past councilor of the Biotechnology Specialty Section of the Society of Toxicology where she was recipient of the section’s first Career Achievement Award. Dr. Cavagnaro is the Founder, Past Chair and current ex-officio member of the leadership committee of BioSafe, an expert preclinical science committee within Bio Organization. She is the Past North American Chair of The Drug Information Association’s Biotech Community and current Research and Development Liaison to the Advisory Council of North America Executive Committee. She is Past Chair of the Clinical and Regulatory Affairs Committee and current member of the Translational Science & Product Development Committee of the American Society of Gene and Cell Therapy. Dr. Cavagnaro was the US BIO representative to the 2006 Association of the British Pharmaceutical Industry/BioIndustry Association Early Stage Clinical Trials Taskforce. She is currently a Chair of Chesapeake Research Review, Inc., an independent Institutional Review Board.
Dr. Cavagnaro obtained her Ph.D. in biochemistry from the University of North Carolina in Chapel Hill, North Carolina and her B.S. in biology from the University of Miami in Coral Gables, Florida.
Dr. Olan, a board-certified Interventional Neuroradiologist, is the director of endovascular and minimally invasive image guided neurosurgery in Washington, D.C. at the George Washington University Medical Center, and is also an associate professor at The George Washington University School of Medicine & Health Sciences. Dr. Olan also serves as a consulting physician to the National Institutes of Health.
Dr. Olan was the director of interventional neuroradiology at Suburban Hospital in Bethesda, Maryland from 1999 to 2010. He is a member of many professional societies including the Radiological Society of North America, American College of Radiology, American Medical Association, Medical Society of District of Columbia, American Society of Neuroradiology, and American Society of Spine Radiology.
Dr. Olan has over 150 published papers, posters, abstracts and lectures on endovascular treatment of cerebrovascular disorders, including the treatment of cerebral aneurysms, arteriovenous malformations, and the treatment of stroke. A great deal of his research has covered the interventional treatment of spinal disorders.
Naiyer Imam, MD is serving as the Chairman and President of First Medicine Inc., an international telemedicine corporation dedicated to virtual physician services and chronic disease management. He previously served as Chairman and CEO of Advanced Medical Imaging and Teleradiology LLC, a new generation teleradiology corporation that he founded in 2009.
Dr. Imam had served as medical director for the publicly traded corporation, NightHawk Radiology Services and was the Chairman and founder of American Teleradiology Nighthawks (ATN), one of the premier pioneering teleradiology companies that have reshaped the field of radiology. American Teleradiology Nighthawks merged with NightHawk Radiology Holdings in September of 2005, and the combined company went public in February 2006 (NASDAQ: NHWK) with market cap over 700M at time of IPO.
Dr. Imam has also served as Chairman of Medical Imaging Specialists, a radiology corporation that he founded in Virginia, which served as a base for a number of imaging centers and surgical centers that Dr. Imam developed. Dr. Imam also served as Chairman of a number of radiology departments at hospitals ranging in size from a large city hospital, Lewis-Gale Medical Center to a rural community hospital, Pulaski Community Hospital.
In 1999, Dr. Imam founded HealthCite.com, a WebMD competitor and medical search engine and knowledge base corporation, and raised 10 million dollars funding from AmGen Corporation for this company. In 2000, Dr. Imam co-founded PanteQ Corporation, a software development company with offices in Boston and New Delhi, India. In 2002, Dr. Imam founded the Center for Advanced Imaging in Roanoke, Virginia. Subsequently, Dr. Imam developed additional imaging centers in Nebraska, Mississippi and Dubai as well as an ambulatory surgical center in Roanoke, Virginia, the Center for Surgical Excellence.
Dr. Imam received a Bachelor’s of Science degree in Mathematics and Computer Science, as well as a medical degree at an accelerated program from Brown University. Dr. Imam obtained a Master of Science degree in Biostatistics at Harvard University. Dr. Imam completed his radiology training at USF in Florida and neuroradiology fellowship at Johns Hopkins Medical Institutions in Baltimore, MD. He also served as an Assistant Professor of Radiology at Johns Hopkins Medical Institutions. Dr. Imam is well published in the medical and radiological literature and is recognized as a leading physician, computer scientist and businessman. Dr. Imam has also developed patent-pending efficiency software for medicine and radiology, including the Virtual Reading Machine.
Dr. Imam assists the Company in establishing strategic relationships with leading physicians, scientists, and medical institutions as well as participating in potential clinical trials and stem cell applications.